PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
21-Mar-2024 DocMorris AG: Significant earnings improvement in 2023; e-prescription is standard in Germany DocMorris AG
20-Mar-2024 Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study Heidelberg Pharma
20-Mar-2024 Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines Bayer AG and Thermo Fisher Scientific Inc
20-Mar-2024 Veeva Vault EDC Surpasses 1,000 Study Start Milestone Veeva Systems
20-Mar-2024 Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty Heidelberg Pharma
20-Mar-2024 OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event OKYO Pharma Limited
20-Mar-2024 Notice of Allowance for Significant POLB 001 Patent in United States Poolbeg Pharma plc
20-Mar-2024 Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies Secarna Pharmaceuticals GmbH & Co. KG
20-Mar-2024 Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche Lonza Group AG
19-Mar-2024 Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024. Eckert & Ziegler SE
19-Mar-2024 Douglas AG: Final offer price for DOUGLAS AG shares set at 26.00 euro per share Douglas AG
19-Mar-2024 Final offer price for DOUGLAS AG shares set at 26.00 euro per share Douglas AG
19-Mar-2024 Douglas AG: Final offer price for DOUGLAS AG shares set at 26.00 euro per share Douglas AG
19-Mar-2024 Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment Mainz BioMed N.V.
19-Mar-2024 Eckert & Ziegler Completes Change of Legal Form to SE Eckert & Ziegler Strahlen- und Medizintechnik AG
19-Mar-2024 ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease ActiTrexx GmbH
19-Mar-2024 Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty Heidelberg Pharma AG
19-Mar-2024 Newron presents 2023 financial results and provides 2024 outlook Newron Pharmaceuticals S.p.A.
19-Mar-2024 PolyPeptide publishes invitation to the annual General Meeting 2024 PolyPeptide Group
18-Mar-2024 Medios acquires Dutch market leader in pharmaceutical compounding services Medios AG